Cipla: Jefferies on Cipla Downgrade to U-P, TP cut to Rs 1170

 27 Jan 2026 09:10 AM

Cipla: Jefferies on Cipla Downgrade to U-P, TP cut to Rs 1170

Cipla: HSBC on Cipla Downgrade to Hold, TP cut to Rs 1285

 27 Jan 2026 09:11 AM

Cipla: HSBC on Cipla Downgrade to Hold, TP cut to Rs 1285

CIPLA: Co In Discussions With Several Partners For CAR-T Cell Therapy Products.

 23 Jan 2026 03:20 PM

CIPLA: Co In Discussions With Several Partners For CAR-T Cell Therapy Products.

Cipla: Co May Venture Into Semaglutide Generics Soon, Partnered With Eli Lilly For Mounjaro Under Yurpeak Brand.

 23 Jan 2026 03:26 PM

Cipla: Co May Venture Into Semaglutide Generics Soon, Partnered With Eli Lilly For Mounjaro Under Yurpeak Brand.

Cipla: Co CEO Says Upcoming Launches To Cushion Grevlimid Rev.

 23 Jan 2026 01:45 PM

Cipla: Co CEO Says Upcoming Launches To Cushion Grevlimid Rev.

Cipla: Co CEO Says Upcoming Launches To Cushion Grevlimid Rev. Decline

 23 Jan 2026 01:45 PM

Cipla: Co CEO Says Upcoming Launches To Cushion Grevlimid Rev. Decline

CIPLA: QUARTERLY BUSINESS WISE SALES PERFORMANCE - NORTH AMERICA SEES A DEGROWTH OF 22% (YOY)

 23 Jan 2026 01:43 PM

CIPLA: QUARTERLY BUSINESS WISE SALES PERFORMANCE - NORTH AMERICA SEES A DEGROWTH OF 22% (YOY)

CIPLA: Q3 EBITDA 12.55B RUPEES VS 19.8B (YOY); EST 15.9B || Q3 EBITDA MARGIN 17.74% VS 28.11% (YOY); EST 22%

 23 Jan 2026 01:29 PM

CIPLA: Q3 EBITDA 12.55B RUPEES VS 19.8B (YOY); EST 15.9B || Q3 EBITDA MARGIN 17.74% VS 28.11% (YOY); EST 22%

CIPLA: CO HAS AN EXCEPTIONAL ITEM OF 2.8B || Q3 PBT 11.7B VS 19B (YOY)

 23 Jan 2026 01:30 PM

CIPLA: CO HAS AN EXCEPTIONAL ITEM OF 2.8B || Q3 PBT 11.7B VS 19B (YOY)

CIPLA: Q3 REVENUE 70.7B RUPEES VS 70.7B (YOY); EST 72.85B

 23 Jan 2026 01:30 PM

CIPLA: Q3 REVENUE 70.7B RUPEES VS 70.7B (YOY); EST 72.85B

CIPLA: Q3 CONS NET PROFIT 6.76B RUPEES VS 15.7B (YOY); EST 11.3B

 23 Jan 2026 01:28 PM

CIPLA: Q3 CONS NET PROFIT 6.76B RUPEES VS 15.7B (YOY); EST 11.3B

Cipla: Nomura Reports Full Class II Recall Of Lanreotide Injection In The U.S. Due To Rising Quality Issues.

 19 Jan 2026 09:39 AM

Cipla: Nomura Reports Full Class II Recall Of Lanreotide Injection In The U.S. Due To Rising Quality Issues.

Cipla: Nomura Reports Lanreotide Is One Of CIPLA's Top U.S. Products With Estimated Yearly Sales Of USD 120–150M; Resupply In H1 FY27 Now Seems Unlikely.

 19 Jan 2026 09:39 AM

Cipla: Nomura Reports Lanreotide Is One Of CIPLA's Top U.S. Products With Estimated Yearly Sales Of USD 120–150M; Resupply In H1 FY27 Now Seems Unlikely.

Cipla: MS on Cipla UW, target price cut to Rs 1292

 16 Jan 2026 09:15 AM

Cipla: MS on Cipla UW, target price cut to Rs 1292

Cipla: Nomura on Cipla Buy, target price Rs 1770

 16 Jan 2026 09:15 AM

Cipla: Nomura on Cipla Buy, target price Rs 1770

Cipla: Nuvama on Cipla Downgrade to reduce, target price cut to Rs 1360

 16 Jan 2026 09:15 AM

Cipla: Nuvama on Cipla Downgrade to reduce, target price cut to Rs 1360

Cipla: USFDA Gives Form 483 To Pharmathen's Greece Plant; Lanreotide Production Paused, Supply Expected Back In First Half Of FY27

 15 Jan 2026 09:47 AM

Cipla: USFDA Gives Form 483 To Pharmathen's Greece Plant; Lanreotide Production Paused, Supply Expected Back In First Half Of FY27

CIPLA: US FDA Issues Form 483 To Pharmathen's Rodopi Facility For Lanreotide Manufacturing, Highlighting 9 Observations Including Data-Integrity Issues That May Affect Cipla's Significant US Revenue From Lanreotide

 07 Jan 2026 09:36 AM

CIPLA: US FDA Issues Form 483 To Pharmathen's Rodopi Facility For Lanreotide Manufacturing, Highlighting 9 Observations Including Data-Integrity Issues That May Affect Cipla's Significant US Revenue From Lanreotide

Cipla: Signs 5-Year Marketing Deal With Pfizer For Four Brands In India

 19 Dec 2025 11:32 AM

Cipla: Signs 5-Year Marketing Deal With Pfizer For Four Brands In India

CIPLA: CO LAUNCHES YURPEAK® (TIRZEPATIDE) FOR THE TREATMENT OF OBESITY AND TYPE 2 DIABETES

 10 Dec 2025 04:07 PM

CIPLA: CO LAUNCHES YURPEAK® (TIRZEPATIDE) FOR THE TREATMENT OF OBESITY AND TYPE 2 DIABETES